Theriva Biologics Inc. (TOVX)
AMEX: TOVX
· Real-Time Price · USD
0.62
-0.19 (-23.46%)
At close: May 08, 2025, 3:59 PM
0.64
2.85%
After-hours: May 08, 2025, 07:06 PM EDT
-23.46% (1D)
| Bid | 0.62 |
| Market Cap | 1.74M |
| Revenue (ttm) | 154K |
| Net Income (ttm) | -25.65M |
| EPS (ttm) | -19.03 |
| PE Ratio (ttm) | -0.03 |
| Forward PE | -0.23 |
| Analyst | Buy |
| Ask | 0.65 |
| Volume | 1,779,484 |
| Avg. Volume (20D) | 784,068 |
| Open | 0.73 |
| Previous Close | 0.81 |
| Day's Range | 0.62 - 0.73 |
| 52-Week Range | 0.62 - 12.25 |
| Beta | 1.15 |
About TOVX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TOVX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TOVX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts18 hours ago
Theriva Biologics shares are trading lower after M...
Unlock content with
Pro Subscription
1 day ago
-40.44%
TOVX stock has given up its prior gain. Theriva Biologics shares were trading higher after the company announced VCN-01 was well tolerated with transient and reversible adverse events, meeting the primary safety endpoint.
1 year ago · proactiveinvestors.com
Theriva Biologics jumps on US FDA approval for pancreatic cancer treatmentTheriva Biologics Inc saw its shares surge over 70% higher in after-hours US trading following news that its lead clinical candidate, VCN-01, has been granted orphan drug designation by the US Food an...
